Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1203 + mFOLFOX6 in first-line metastatic colorectal cancer
NCT04233151Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2020
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ql1203 in metastatic colorectal cancer (mCRC), sponsored by Qilu Pharmaceutical. Status: unknown.
02
Drugs
ql1203
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04233151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04233151.